MarketCap
Facebook
X
Telegram
Epizyme Operating Income | EPZM
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Epizyme
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -238 M | -225 M | -177 M | -128 M | -137 M | -112 M | -133 M | -55 M | -3.13 M | -768 K | -21 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -768 K | -238 M | -112 M |
Quarterly Operating Income Epizyme
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -29.8 M | -50.9 M | - | -64.1 M | -58.2 M | -64.3 M | -62.1 M | -54.4 M | -57.6 M | -51.4 M | -57.5 M | -38 M | -50.7 M | -31 M | -24.3 M | -38.6 M | -30.3 M | -35 M | -37.4 M | -38.1 M | -28.5 M | -33 M | -35.5 M | -24.8 M | -28.4 M | -23.1 M | -22.3 M | -23.1 M | -25.8 M | -61.4 M | -15.1 M | -19.7 M | -13.3 M | -6.91 M | 16.3 M | -9.73 M | -2.18 M | -7.48 M | -4.54 M | 4.44 M | 4.8 M | -5.48 M | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 16.3 M | -64.3 M | -30.2 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Graybug Vision
GRAY
|
-23.1 M | - | -11.23 % | $ 9.65 M |  USA |
 |
Galera Therapeutics
GRTX
|
-2.54 M | - | -32.59 % | $ 7.61 M | USA |
 |
Happiness Biotech Group Limited
HAPP
|
-14.7 M | - | 1.35 % | $ 17.8 M |  China |
 |
Hepion Pharmaceuticals
HEPA
|
-4.16 M | - | -18.79 % | $ 39.3 K | USA |
 |
Hoth Therapeutics
HOTH
|
-12.4 M | - | - | $ 18.8 M | USA |
 |
IMARA
IMRA
|
-120 M | - | 15.96 % | $ 663 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
-112 M | - | - | $ 1.45 B |  Britain |
 |
KemPharm
KMPH
|
-62.9 M | - | -0.34 % | $ 200 M | USA |
 |
Kezar Life Sciences
KZR
|
-59.1 M | - | - | $ 53.3 M | USA |
 |
Lixte Biotechnology Holdings
LIXT
|
-5.11 M | - | - | $ 63.4 M | USA |
 |
Magenta Therapeutics
MGTA
|
-178 M | - | -7.74 % | $ 41.6 M | USA |
 |
NovaBay Pharmaceuticals
NBY
|
-8.44 M | - | - | $ 11.3 M | USA |
 |
NeuroBo Pharmaceuticals
NRBO
|
-13.7 M | - | 0.43 % | $ 12 M | USA |
 |
OncoCyte Corporation
OCX
|
-51.1 M | - | 17.22 % | $ 355 K | USA |
 |
Onconova Therapeutics
ONTX
|
-17.9 M | - | -0.47 % | $ 21 M | USA |
 |
Opthea Limited
OPT
|
-156 M | - | - | $ 1.2 B |  Australia |
|
BiomX
PHGE
|
-41.5 M | $ 1.85 | 14.2 % | $ 3.02 M |  Israel |
 |
Pieris Pharmaceuticals
PIRS
|
-38.6 M | - | -15.58 % | $ 1.22 B |  Germany |
 |
Plus Therapeutics
PSTV
|
-15.3 M | - | - | $ 301 M | USA |
 |
Pluristem Therapeutics
PSTI
|
-24.9 M | - | -1.9 % | $ 33.3 M | Israel |
 |
Qualigen Therapeutics
QLGN
|
-13.2 M | - | 5.59 % | $ 1.16 M | USA |
|
Qilian International Holding Group Limited
QLI
|
-12.6 M | - | -6.08 % | $ 184 M | China |
 |
Cassava Sciences
SAVA
|
-95.4 M | - | - | $ 110 M | USA |
 |
Selecta Biosciences
SELB
|
-143 M | - | -8.69 % | $ 126 M | USA |
 |
Sangamo Therapeutics
SGMO
|
-121 M | - | - | $ 50.4 M | USA |
 |
Salarius Pharmaceuticals
SLRX
|
-12.6 M | - | - | $ 2.64 M | USA |
 |
Sensei Biotherapeutics
SNSE
|
-22.3 M | - | - | $ 17.5 M | USA |
 |
Sonnet BioTherapeutics Holdings
SONN
|
-15.8 M | - | - | $ 826 K | USA |
 |
Synthetic Biologics
SYN
|
-24.1 M | - | 1.32 % | $ 16.2 M | USA |
 |
Synlogic
SYBX
|
-4.01 M | - | - | $ 7.07 M | USA |
 |
Virios Therapeutics, LLC
VIRI
|
-28 M | - | 2710.01 % | $ 72.9 M | USA |
 |
Vallon Pharmaceuticals
VLON
|
-12 M | - | -6.47 % | $ 5.76 M | USA |
 |
Vaxart
VXRT
|
5.17 M | - | -25.06 % | $ 46.3 M | USA |
 |
XOMA Corporation
XOMA
|
11.4 M | - | - | $ 485 M | USA |
 |
Repare Therapeutics
RPTX
|
-93.5 M | - | - | $ 112 M |  Canada |
 |
Sesen Bio
SESN
|
-62.2 M | - | 7.29 % | $ 127 M | USA |
|
Windtree Therapeutics
WINT
|
-26.1 M | - | - | $ 26.8 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
-80.7 M | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
-66.6 M | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
-8.67 M | - | - | $ 13 M | USA |
 |
Lyra Therapeutics
LYRA
|
-31 M | - | - | $ 24.9 M | USA |
 |
Brickell Biotech
BBI
|
-6.36 M | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
-104 M | - | - | $ 8.42 M | USA |